The present invention encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition comprises CPV virus-like particles (VLPs) and a CPV modified-live virus (MLV), and are capable of overcoming maternally-derived antibodies (MDAs). The invention encompasses a preparation method and a use thereof. The CPV VLPs provided by the invention may be formed by the CPV VP2 protein.